The main objective in the development of nanoparticles is drug targeting. As mentioned in the Introduction drug targeting enables high concentrations at the target site, that is, the desired place or action, whereas only little drug is distributed to the rest of the body. This can be done using the natural passive distribution pattern of the body for the carrier and therefore it is called passive targeting [7, 282]. However, the target sites that can be reached by this approach are very limited. Active targeting refers to the distribution achieved after the natural distribution pattern has been modified by alteration of the surface properties, binding of ligands, employment of magnetic nanoparticles, etc. For this reason, many more target sites can be reached or the drug concentrations at the target are much higher.
Was this article helpful?